Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 34 results.
User Information
Export Records
  1. 1.   Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterization
  2. Becker, William; Olkhanud, Purevdorj B; Seishima, Noriko; Moreno, Paloma A; Goldfarbmuren,Kate; Maeng, Hoyoung M; Berzofsky, Jay A
  3. Journal for Immunotherapy of Cancer. 2024, Jul 01; 12(7):
  1. 2.   Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas
  2. Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Meehan, Robert S; Do, Khanh; Collins, Jerry M; Anderson, Larry; Ishii, Kazusa; Takebe, Naoko; Zlott, Jennifer; Juwara,Lamin; Piekarz, Richard; Streicher, Howard; Sharon, Elad; Rubinstein, Larry; Voth,Andrea; Lozier, Jay; Dull,Angie; Wilsker,Deborah; Hinoue, Toshinori; Laird, Peter W; Ferry-Galow,Katherine; Kinders,Robert; Parchment,Ralph; Doroshow,Jim; Chen, Alice P
  3. Oncotarget. 2020, Nov 03; 11(44): 3959-3971.
  1. 3.   Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model
  2. Zhu, Guangwei; Zhao, Ming; Han, Qinghong; Tan, Yuying; Sun, Y U; Bouvet, Michael; Clary, Bryan; Singh,Shree Ram; Ye, Jianxin; Hoffman, Robert M
  3. Anticancer research. 2019, Dec; 39(12): 6463-6470.
  1. 4.   Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model
  2. Zhu, Guangwei; Zhao, Ming; Han, Qinghong; Tan, Yuying; Sun, Y U; Bouvet, Michael; Singh,Shree Ram; Ye, Jianxin; Hoffman, Robert M
  3. Anticancer research. 2019, Nov; 39(11): 5999-6005.
  1. 5.   Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model
  2. Higuchi, Takashi; Sugisawa, Norihiko; Miyake, Kentaro; Oshiro, Hiromichi; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Kline,Zoey; Belt,Paige; Chawla, Sant P; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Anticancer research. 2019, Sep; 39(9): 4781-4786.
  1. 6.   Sorafenib and Palbociclib Combination Regresses a Cisplatinum-resistant Osteosarcoma in a PDOX Mouse Model
  2. Higuchi, Takashi; Sugisawa, Norihiko; Miyake, Kentaro; Oshiro, Hiromichi; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Chawla, Sant P; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Anticancer research. 2019, Aug; 39(8): 4079-4084.
  1. 7.   Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Sugisawa, Norihiko; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Bouvet, Michael; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Cancer letters. 2019, Jun 1; 451: 122-127.
  1. 8.   Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model
  2. Higuchi, Takashi; Miyake, Kentaro; Oshiro, Hiromichi; Sugisawa, Norihiko; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Igarashi, Kentaro; Chawla, Sant P.; Bouvet, Michael; Singh,Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M.
  3. Biochemical and biophysical research communications. 2019, MAY 28; 513(2): 326-331.
  1. 9.   The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model
  2. Higuchi, Takashi; Kawaguchi, Kei; Miyake, Kentaro; Oshiro, Hiromichi; Zhang, Zhiying; Razmjooei, Sahar; Wangsiricharoen, Sintawat; Igarashi, Kentaro; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Nelson, Scott D; Dry, Sarah M; Li, Yunfeng; Chawla, Sant P; Eilber, Frederick C; Singh, Shree Ram; Tsuchiya, Hiroyuki; Hoffman, Robert M
  3. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2019, Jan 04; 111: 835-840.
  1. 10.   Predicting tumor cell line response to drug pairs with deep learning
  2. Xia, Fangfang; Shukla, Maulik; Brettin, Thomas; Garcia-Cardona, Cristina; Cohn, Judith; Allen, Jonathan E.; Maslov, Sergei; Holbeck, Susan L.; Doroshow, Jim; Evrard, Yvonne; Stahlberg, Eric; Stevens, Rick L.
  3. BMC bioinformatics. 2018, Dec 21; 19(Supp 18):
  1. 11.   Design of a multicompartment hydrogel that facilitates time-resolved delivery of combination therapy and synergized killing of glioblastoma
  2. Majumder, Poulami; Baxa, Ulrich; Walsh, Scott; Schneider, Joel
  3. Angewandte Chemie (International ed. in English). 2018, Nov 12; 57(46): 15040-15044.
  1. 12.   Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
  2. Koelsch, K. K.; Boesecke, C.; McBride, K.; Gelgor, L.; Fahey, P.; Natarajan, V.; Baker, D.; Bloch, M.; Murray, J. M.; Zaunders, J.; Emery, S.; Cooper, D. A.; Kelleher, A. D.; Team, P. S.
  3. Aids. 2011, Nov; 25(17): 2069-2078.
  1. 13.   The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
  2. Gril, B.; Palmieri, D.; Qian, Y.; Anwar, T.; Ileva, L.; Bernardo, M.; Choyke, P.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S.
  3. Plos One. 2011, Oct; 6(10): 11.
  1. 14.   Genetic Diversity of Simian Immunodeficiency Virus Encoding HIV-1 Reverse Transcriptase Persists in Macaques despite Antiretroviral Therapy
  2. Kearney, M.; Spindler, J.; Shao, W.; Maldarelli, F.; Palmer, S.; Hu, S. L.; Lifson, J. D.; KewalRamani, V. N.; Mellors, J. W.; Coffin, J. M.; Ambrose, Z.
  3. Journal of Virology. 2011, Jan; 85(2): 1067-1076.
  1. 15.   Authentic HIV-1 integrase inhibitors
  2. Liao, C. Z.; March, C.; Burke, T. R.; Pommier, Y.; Nicklaus, M. C.
  3. Future Medicinal Chemistry. 2010, Jul; 2(7): 1107-1122.
  1. 16.   Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2a in HIV-1-Monoinfected Participants: A Phase II Clinical Trial
  2. Asmuth, D. M.; Murphy, R. L.; Rosenkranz, S. L.; Lertora, J. J. L.; Kottilil, S.; Cramer, Y.; Chan, E. S.; Schooley, R. T.; Rinaldo, C. R.; Thielman, N.; Li, X. D.; Wahl, S. M.; Shore, J.; Janik, J.; Lempicki, R. A.; Simpson, Y.; Pollard, R. B.; Tea, A. C. T. G. A.
  3. Journal of Infectious Diseases. 2010, Jun 1; 201(11): 1686-1696.
  1. 17.   Identification of a Potential Pharmacological Sanctuary for HIV Type 1 in a Fraction of CD4(+) Primary Cells
  2. Valentin, A.; Morrow, M.; Poirier, R. H.; Aleman, K.; Little, R.; Yarchoan, R.; Pavlakis, G. N.
  3. Aids Research and Human Retroviruses. 2010, Jan; 26(1): 79-88.
  1. 18.   Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance
  2. Das, K.; Bandwar, R. P.; White, K. L.; Feng, J. Y.; Sarafianos, S. G.; Tuske, S.; Tu, X. Y.; Clark, A. D.; Boyer, P. L.; Hou, X. R.; Gaffney, B. L.; Jones, R. A.; Miller, M. D.; Hughes, S. H.; Arnold, E.
  3. Journal of Biological Chemistry. 2009 284(50): 35092-35100.
  1. 19.   Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
  2. Palmer, S.; Malclarelli, F.; Wiegand, A.; Bernstein, B.; Hanna, G. J.; Brun, S. C.; Kempf, D. J.; Mellors, J. W.; Coffin, J. M.; King, M. S.
  3. Proceedings of the National Academy of Sciences of the United States of America. 2008 105(10): 3879-3884.
  1. 20.   ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
  2. Maldarelli, F.; Palmer, S.; King, M. S.; Wiegand, A.; Polis, M. A.; Mican, J. A.; Kovacs, J. A.; Davey, R. T.; Rock-Kress, D.; Dewar, R.; Liu, S. Y.; Metcalf, J. A.; Rehm, C.; Brun, S. C.; Hanna, G. J.; Kempf, D. J.; Coffin, J. M.; Mellors, J. W.
  3. Plos Pathogens. 2007, Apr; 3(4): 484-488.
  1. 21.   Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097
  2. Das, K.; Sarafianos, S. G.; Clark, A. D.; Boyer, P. L.; Hughes, S. H.; Arnold, E.
  3. Journal of Molecular Biology. 2007, Jan; 365(1): 77-89.
  1. 22.   Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: In vitro and in vivo correlation
  2. Meletiadis, J.; Petraitis, V.; Petraitiene, R.; Lin, P.; Stergiopoulou, T.; Kelaher, A. M.; Sein, T.; Schaufele, R. L.; Bacher, J.; Walsh, T. J.
  3. Journal of Infectious Diseases. 2006, Oct; 194(7): 1008-1018.
  1. 23.   Cancer proteomics: many technologies, one goal
  2. Conrads, T. P.; Hood, B. L.; Petricoin, E. F.; Liotto, L. A.; Veenstra, T. D.
  3. Expert Review of Proteomics. 2005, Oct; 2(5): 693-703.
  1. 24.   Effects of the Delta 67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision
  2. Boyer, P. L.; Imamichi, T.; Sarafianos, S. G.; Arnold, E.; Hughes, S. H.
  3. Journal of Virology. 2004, SEP; 78(18): 9987-9997.
  1. 25.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel